Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families-Reference-Cited by-同舟云学术

Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families

Published:1994-12 Issue:4 Volume:8 Page:392-398
ISSN:1061-4036
Container-title:Nature Genetics
language:en
Short-container-title:Nat Genet

Author:

Simard J.,Tonin P.,Durocher F.,Morgan K.,Rommens J.,Gingras S.,Samson C.,Leblanc J.-F.,Bélanger C.,Dion F.,Liu Q.,Skolnick M.,Goldgar D.,Shattuck-Eidens D.,Labrie F.,Narod S.A.

Publisher

Springer Science and Business Media LLC

Subject

Genetics

Link

http://www.nature.com/articles/ng1294-392.pdf

Reference14 articles.

1. Hall, J.M. et al. Linkage analysis of early onset familial breast cancer to chromosome 17q21. Science 250, 1684–1689 (1990).

2. Narod, S.A. et al. Familial breast-ovarian cancer locus on chromosome 17q12–23. Lancet 338, 82–83 (1991).

3. Miki, Y. et al. A strong candidate gene for the breast and ovarian cancer susceptibility gene BRCA1. Science 266, 66–71 (1994).

4. Narod, S.A. et al. A heterogeneity analysis of 145 breast-ovarian cancer families. Am. J. hum. Genet. (in the press).

5. Tonin, P. et al. Linkage analysis of 26 Canadian breast and breast-ovarian cancer families. Hum. Genet. (in the press).

Cited by 271 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mutations of BRCA1, BRCA2, and PALB2 Genes in Breast Tumor Tissue: Relationship with the Effectiveness of Neoadjuvant Chemotherapy and Disease Prognosis;Genes;2023-07-28

2. BRCA1 promoter methylation & its immunohistochemical correlation in sporadic breast cancer;Indian Journal of Medical Research;2023

3. Loss of Heterozygosity ofBRCA1/2as a Predictive Marker for Talazoparib Response;Anticancer Research;2022-10-26

4. C. elegans as a model organism to study female reproductive health;Comparative Biochemistry and Physiology Part A: Molecular & Integrative Physiology;2022-04

5. Case Report Series: Aggressive HR Deficient Colorectal Cancers Related to BRCA1 Pathogenic Germline Variants;Frontiers in Oncology;2022-02-24